urea has been researched along with piperidines in 238 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (9.66) | 18.7374 |
| 1990's | 3 (1.26) | 18.2507 |
| 2000's | 50 (21.01) | 29.6817 |
| 2010's | 117 (49.16) | 24.3611 |
| 2020's | 45 (18.91) | 2.80 |
| Authors | Studies |
|---|---|
| Kehrhahn, OH; Kubinyi, H | 1 |
| Manners, JM; Wills, A | 1 |
| Lichtenstein, GI; Polianovsky, OL; Timofeev, VP; Volkenstein, MV | 1 |
| Berliner, LJ | 1 |
| Belágyi, J | 1 |
| Kempfle, B; Reschke, L; Schmidtmann, W | 1 |
| Chimitova, TA; Grachev, MA; Knorre, DG | 1 |
| Casagrande, C; Ferrari, G; Ferrini, R; Galli, A; Miragoli, G | 1 |
| Hicks, BH; Jarrett, RJ; Keen, H; Ward, JD; Wise, P | 1 |
| Conrad, E; Keefer, L; Lijinsky, W; Van de Bogart, R | 1 |
| Leistner, S; Wagner, G | 1 |
| Anthony, M; Lance, JW; Somerville, B | 1 |
| Danielsson, B | 1 |
| Gerber, CF; Laubach, GD; McFarland, JW; McLamore, WM; McManus, JM | 1 |
| Gerber, CF; McFarland, JW; McLamore, WM | 1 |
| Fuller, RW; Hemrick-Luecke, SK | 1 |
| Ruetten, H; Thiemermann, C | 1 |
| Marcoli, M; Maura, G; Raiteri, M; Tortarolo, M | 1 |
| Kanki, H; Mitamura, H; Ogawa, S; Sueyoshi, K; Takatsuki, S | 1 |
| Ashby, CR; Katsumori, H; Minabe, Y; Watanabe, K | 1 |
| Bauman, JG; Buckman, B; Dunning, L; Ghannam, A; Green, C; Hesselgesser, J; Horuk, R; Islam, I; Liang, M; May, K; Morrissey, MM; Ng, HP; Perez, HD; Rosser, M; Shurey, S; Snider, RM; Wei, GP; Xu, W | 1 |
| Ashwell, MA; Han, S; Largis, E; Mulvey, R; Solvibile, WR; Tillet, J | 1 |
| Itoh, K; Oguchi, T; Tozuka, Y; Yamamoto, K | 2 |
| Covington, M; Davies, P; De Lucca, GV; Decicco, CP; Johnson, C; Kim, UT; Ko, SS; Newton, RC; Solomon, KA; Trainor, GL; Vargo, BJ; Welch, PK | 1 |
| Itoh, K; Matsui, S; Oguchi, T; Tozuka, Y; Yamamoto, K | 1 |
| Sun, CM | 1 |
| Adachi, K; Fujishiro, H; Kinoshita, Y; Komazawa, Y; Mihara, T | 1 |
| Fang, M; Fisher, LL; Kovács, KJ; Larson, AA | 1 |
| ELSASSER, G | 1 |
| VELTMAN, G | 1 |
| FUJIMOTO, JM; SERRONE, DM | 1 |
| BAUMLER, J; RIPPSTEIN, S | 1 |
| STOLK, DP | 1 |
| ASATOOR, AM; MILNE, MD; SIMENHOFF, ML; ZILVA, JF | 1 |
| FINGER, H; FRETZDORFF, AM; SCHNEIDER, F; SEYNSCHE, K; WEITZEL, G | 1 |
| Clark, CM; Covington, M; Davies, P; Decicco, CP; Duncia, JV; Estrella, M; Gardner, DS; Ko, SS; Newton, RC; Santella, JB; Solomon, K; Stowell, N; Trainor, GL; Varnes, JG; Wacker, DA; Wadman, E; Watson, PS; Welch, P | 1 |
| KRUIZINGA, EE | 1 |
| Burrows, JN; Cumming, JG; Fillery, SM; Hamlin, GA; Hudson, JA; Jackson, RJ; McLaughlin, S; Shaw, JS | 1 |
| Batt, DG; Carter, PH; Davies, P; Decicco, CP; Houghton, GC; Orlovsky, YI; Roderick, J; Santella, JB; Trzaskos, JM; Wacker, DA; Wadman, EA; Welch, PK | 1 |
| Covington, M; Das, AM; Davies, P; De Lucca, GV; Decicco, CP; Duncia, JV; Emmett, G; Gardner, DS; Graden, DM; Kim, UT; Ko, SS; Liauw, A; Newton, RC; Santella, JB; Solomon, KA; Stowell, NC; Trainor, GL; Vargo, BJ; Wacker, DA; Wadman, EA; Wang, Z; Welch, PK; Yeleswaram, S; Zheng, C | 1 |
| Andersson, CM; Brann, MR; Burstein, ES; Davis, RE; Del Tredici, AL; Gardell, LR; Geyer, MA; Harvey, SC; Lameh, J; Makhay, M; Ott, TR; Piu, F; Powell, SB; Schiffer, HH; Schlienger, N; Son, TY; Thygesen, MB; Tolf, BR; Uldam, AK; Vanover, KE; Veinbergs, I; Weiner, DM | 1 |
| Roy, K; Thomas Leonard, J | 1 |
| Roberts, C | 1 |
| Brun, R; Charman, SA; Charman, WN; Chollet, J; Creek, DJ; Dong, Y; Matile, H; Padmanilayam, M; Scheurer, C; Scorneaux, B; Tomas, JS; Vennerstrom, JL; Wittlin, S | 1 |
| Allen, DR; Bolt, A; Chapman, GA; Knight, RL; Meissner, JW; Owen, DA; Watson, RJ | 1 |
| Agrawal, A; Aher, YD; Bharatam, PV; Garg, P | 1 |
| Afantitis, A; Igglessi-Markopoulou, O; Koutentis, PA; Markopoulos, J; Melagraki, G; Sarimveis, H | 1 |
| Aldana, I; Ceras, J; Cirauqui, N; Galiano, S; Juanenea, L; Monge, A; Pérez, S; Rivera, G | 1 |
| Davis, RE; Mant, TG; Robbins-Weilert, D; van Kammen, DP; Vanover, KE; Weiner, DM; Wilbraham, DG | 2 |
| Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I | 1 |
| Alves, AP; Bezerra, DP; Costa-Lotufo, LV; de Alencar, NM; de Castro, FO; de Moraes, MO; Elmiro, FJ; Lima, MA; Lima, MW; Mesquita, RO; Pessoa, C; Silveira, ER | 1 |
| Brann, MR; Davis, RE; Farde, L; Hacksell, U; Halldin, C; Jovanovic, H; Karlsson, P; Mansson, M; Nordstrom, AL; Vanover, KE; Weiner, DM | 1 |
| Allen, DR; Birch, HL; Chapman, GA; Galvin, FC; Jopling, LA; Knight, RL; Meier, D; Meissner, JW; Oliver, K; Owen, DA; Thomas, EJ; Tremayne, N; Watson, RJ; Williams, SC | 1 |
| Carter, PH; Davies, P; Decicco, CP; DeLucca, GV; Duncia, JV; Gardner, DS; Graden, DM; Kariv, I; Ko, SS; Mandlekar, S; Reddy, P; Santella, JB; Shi, C; Solomon, KA; Tebben, AJ; Wacker, DA; Wadman, EA; Watson, PS; Welch, PK; Yao, W; Yeleswaram, S | 1 |
| Batt, DG; Carter, PH; Davies, P; Duncia, JV; Gardner, DS; Ko, SS; Santella, JB; Tebben, AJ; Traeger, SC; Wadman, EA; Welch, PK | 1 |
| Poyurovsky, M; Weizman, A; Weizman, R | 1 |
| Hu, R; Ruan, X; Yuan, Y; Zhang, R | 1 |
| Antonucci, A; Delogu, G; Elli, M; Giuliana, G; Lauria, D; Lubrano, R; Marandola, M; Santulli, M; Tellan, G | 1 |
| Betz, AJ; Bibbiani, F; Chase, TN; Davis, RE; Kielaite, A; Salamone, JD; Vanover, KE; Weber, SM; Weiner, DM | 1 |
| Kawaguchi, M; Kazama, T; Masui, K; Takamatsu, I | 1 |
| Hasserodt, J; Waibel, M | 1 |
| Camp, HS; Cao, N; Collins, CA; Janis, RS; Liu, B; Liu, G; Liu, M; Nelson, LT; Serby, MD; Sham, HL; Smith, HT; Suhar, TS; Surowy, TK; Szczepankiewicz, BG; Xin, Z; Zhao, H | 1 |
| Cai, L; Hertz, L; Li, B; Nu, W; Peng, L; Zhang, H; Zhang, S | 1 |
| Brady, AE; Bridges, TM; Conn, PJ; Daniels, RN; Lindsley, CW; Miller, NR | 1 |
| Barrish, JC; Carter, PH; Davies, P; Dhar, TG; Gougoutas, JZ; Malley, MF; Wu, DR; Yang, G | 1 |
| Abbas, A; Roth, BL | 1 |
| Chauthaiwale, V; Dutt, C; Gupta, RC; Munshi, S; Odedara, R; Patel, J; Shinde, P; Sonawane, R; Srivastava, SK; Tuli, D; Zambad, SP | 1 |
| Ahn, K; Beidler, D; Cravatt, BF; Dunbar, JB; Fay, L; Gregory, T; Johnson, DS; Kesten, S; Lazerwith, SE; Liimatta, M; Morris, M; Nomanbhoy, TK; Smith, S; Song, Y; Stiff, C | 1 |
| Ahn, K; Beidler, D; Bhattacharya, K; Cravatt, BF; Johnson, DS; Kamtekar, S; Lazerwith, S; Liimatta, M; Long, JZ; McKinney, MK; Mileni, M; Sadagopan, N; Smith, SE; Stevens, RC; Stiff, C; Swaney, S; Van Becelaere, K; Weerapana, E; Zhang, Y | 1 |
| Fukami, T; Gomori, A; Haga, Y; Hirohashi, T; Ishihara, A; Ishii, Y; Iwaasa, H; Kanatani, A; Moriya, M; Nonoshita, K; Ohe, T; Okamoto, O; Sakamoto, T; Sakuraba, A; Shibata, T; Suga, T; Takahashi, H; Takahashi, T | 1 |
| Berglund, S; Egner, BJ; Giordanetto, F; Gradén, H; Gradén, J; Inghardt, T; Morgan, DG | 1 |
| Benwell, K; Brooks, T; D'Alessandro, J; Dokurno, P; Francis, G; Gibbons, B; Hart, T; Haymes, T; Kennett, G; Lightowler, S; Macias, AT; Mansell, H; Matassova, N; Misra, A; Padfield, A; Parsons, R; Pratt, R; Robertson, A; Roughley, S; Walls, S; Wong, M | 1 |
| Alonso-Galicia, M; Berger, JP; Chen, HS; Chen, X; Chen, Y; Colletti, SL; Deng, Q; Ding, FX; Kumar, S; Mitra, K; Pai, LY; Roy, S; Shen, HC; Soisson, SM; Stevenson, AS; Tata, JR; Tong, V; Tong, X; Tsai, C; Wang, S; Xu, S; Zhang, B; Zhang, X; Zhou, G | 1 |
| Alonso-Galicia, M; Berger, JP; Chen, HS; Chen, Y; Colletti, SL; Deng, Q; Ding, FX; Pai, LY; Roy, S; Shen, HC; Tata, JR; Tong, V; Tong, X; Xu, S; Zhang, B; Zhang, X; Zhou, G | 1 |
| Ashwell, S; Brassil, PJ; Dai, J; Garner, CE; Gönen, M; Goteti, K; Kern, SE; Moustakas, DT; Schwartz, GK; Utley, L; Zabludoff, S | 1 |
| Horiguchi, M; Huang, M; Li, Z; Meltzer, HY; Neill, JC; Shahid, M; Snigdha, S | 1 |
| Bahr, D; Friedman, JH; Johnson, A; Meltzer, HY; Mills, R; Revell, S; Williams, H | 1 |
| De Lombaert, S; Eldrup, AB; Farrow, NA; Kukulka, A; Soleymanzadeh, F | 1 |
| Aslanian, R; Berlin, M; Boyce, CW; Korfmacher, W; Lee, YJ; McCormick, KD; Sorota, S; Wang, Y; West, RE; Williams, SM | 1 |
| Burn, DJ; Docherty, MJ | 1 |
| Beattie, RE; Knopp, K; Liu, B; Sher, E; Ursu, D | 1 |
| Allen, AM; Oldfield, BJ; Verty, AN | 1 |
| Hammock, BD; Inceoglu, B; Jones, PD; Liu, JY; Morisseau, C; Rose, TE; Sanborn, JR | 1 |
| Fujisaki, Y; Fuyuki, R; Hashimoto, K; Horii, Y; Nagai, K; Nakashima, T; Niijima, A; Shen, J; Tanida, M | 1 |
| Haghparast, A; Hassanpour-Ezatti, M; Safari, MS; Taslimi, Z | 1 |
| Milligan, G; Pediani, JD; Ward, RJ | 1 |
| Ancoli-Israel, S; Davis, RE; van Kammen, DP; Vanover, KE; Weiner, DM | 1 |
| D'Anna, F; Frenna, V; Ghelfi, F; Marullo, S; Spinelli, D | 1 |
| Ahn, K; Beidler, D; Bhattachar, SN; Blankman, JL; Cravatt, BF; Dudley, DT; Johnson, DS; Liimatta, MB; Nomanbhoy, TK; Nomura, DK; Sadagopan, N; Smith, SE; Stiff, C; Swaney, S; Van Becelaere, K; Weerapana, E; Wren, P; Young, T; Zhang, Y | 1 |
| Arnt, J; Ebdrup, BH; Glenthøj, B; Rasmussen, H | 1 |
| Branduardi, D; Cavalli, A; De Vivo, M; Lodola, A; Masetti, M; Mor, M; Palermo, G; Piomelli, D | 1 |
| Adams, MR; Appt, S; Dong, H; Fortenbach, C; Hammock, BD; Hwang, SH; Jones, PD; Lango, J; Miyabe, C; Morisseau, C; Rose, TE; Tsai, HJ; Ulu, A; Yang, J | 1 |
| Bonhaus, DW; McFarland, K; Price, DL | 2 |
| Chiou, LC; Fu, SY; Ho, YC; Lee, HJ; Liao, HT; Liao, YY; Mackie, K; Teng, SF; Tung, LW | 1 |
| Prakash, CR; Raja, S | 1 |
| Bortoff, K; Fennell, T; Fulp, A; Maitra, R; Mathews, J; Seltzman, H; Snyder, R; Zhang, Y | 1 |
| Nishiyama, Y | 1 |
| Chen, J; Leng, Y; Ning, M; Shen, J; Zhang, L; Zou, Q | 1 |
| Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY | 1 |
| Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM | 1 |
| Garcia-Bereguiain, MA; Gonzalez-Islas, C; Wenner, P | 1 |
| Antonini, A; Koutsikos, K; Pilleri, M | 1 |
| Deng, SX; Hammock, BD; Morisseau, C; Newcomer, ME; Pakhomova, S; Pecic, S; Rinderspacher, A; Zhu, Z | 1 |
| Krishnamurthi, N; Lieberman, A | 1 |
| Berrendero, F; Flores, Á; Maldonado, R; Martín-García, E; Plaza-Zabala, A; Saravia, R | 1 |
| Aaltonen, N; Häyrinen, J; Käsnänen, H; Korhonen, J; Kuusisto, A; Laitinen, JT; Laitinen, T; Lehtonen, M; Navia-Paldanius, D; Nevalainen, T; Pantsar, T; Pasonen-Seppänen, S; Poso, A; Ribas, CR; Rönkkö, J; Savinainen, JR; Takabe, P | 1 |
| Hacksell, U; Hubbard, D; McFarland, K | 1 |
| Brown, RK; Freire, E; Hutchins, BM; Schön, A | 1 |
| Friedman, JH | 2 |
| Cravatt, BF; Hsu, KL; Inloes, J; Pugh, H; Speers, AE; Tsuboi, K; Whitby, LR | 1 |
| Chang, JW; Cravatt, BF; Hsu, KL; Pugh, H; Speers, AE; Tsuboi, K; Whitby, LR | 1 |
| Conway, JG; Demarest, KT; Gaul, MD; Ho, G; Kuo, GH; Lenhard, JM; Li, Y; Liang, Y; Lu, H; Murray, WV; Tang, Y; Yang, SM; Zhang, R | 1 |
| Ballard, C; Chi-Burris, K; Corbett, A; Cummings, J; Dhall, R; Isaacson, S; Mills, R; Williams, H | 1 |
| Fox, SH | 1 |
| Kingwell, K | 1 |
| Chang, M; Hua, J; Huang, CS; L'Heureux, A; Lam, PY; Lapointe, P; Martel, A; Price, LA; Qiao, JX; Rehfuss, R; Ruel, R; Thibeault, C; Wexler, RR; Wu, Q; Zheng, J | 1 |
| Meltzer, HY; Roth, BL | 1 |
| Burstein, ES; Hacksell, U; McFarland, K; Mills, RG; Williams, H | 1 |
| Borek, LL; Friedman, JH | 1 |
| An, Y; Barrish, JC; Briceno, SW; Caceres-Cortes, J; Camac, DM; Caporuscio, C; Carter, PH; Cavallaro, C; Cvijic, ME; Davies, P; Dhar, M; Duncia, JV; Foster, WR; Gardner, DS; Grafstrom, RR; Hynes, J; Khan, JA; Liu, R; Patel, SR; Rose, AV; Santella, JB; Tebben, AJ; Vickery, RD; Watson, AJ; Wu, H; Yang, G; Yarde, M | 1 |
| Horiguchi, M; Meltzer, HY; Miyauchi, M; Oyamada, Y; Rajagopal, L | 1 |
| Andersen, VL; Dyssegaard, A; Hansen, HD; Herth, MM; Knudsen, GM; Kristensen, JL | 1 |
| Butterworth, S; Clayden, J; Tait, MB | 1 |
| Aungier, SR; Cartwright, AJ; Ito, K; Midwood, KS; To, WS | 1 |
| Balboni, G; Congiu, C; De Petrocellis, L; Di Marzo, V; Onnis, V; Schiano-Moriello, A | 1 |
| Cummings, J; Zhong, K | 1 |
| Ballard, C; Burn, DJ; Coate, B; Corbett, A; Isaacson, S; Mills, R; Pahwa, R; Rascol, O; Williams, H | 1 |
| Ali Reza, M; Azizi, H; Mirnajafi-Zadeh, J; Mohammad-Pour Kargar, H; Semnanian, S | 1 |
| Aston-Jones, G; Bentzley, BS; Porter-Stransky, KA | 1 |
| Anderson, KC; Cox, A; Hunter, NS | 1 |
| Giordano, A; Morales, F | 1 |
| Stevens, J | 1 |
| Benyhe, S; Carradori, S; De Petrocellis, L; Dvorácskó, S; Erdei, AI; Fidanza, L; Marzoli, F; Mirzaie, S; Mollica, A; Monti, L; Novellino, E; Ötvös, F; Pieretti, S; Samavati, R; Schiano Moriello, A; Stefanucci, A; Szűcs, E; Tömböly, C; Zádor, F | 1 |
| Banks, ML | 1 |
| Howland, RH | 1 |
| Traynor, K | 1 |
| Markham, A | 1 |
| Esmaeili, MH; Ezzatpanah, S; Haghparast, A; Reisi, Z | 1 |
| Stahl, SM | 2 |
| Chendo, I; Ferreira, JJ | 1 |
| Majlath, Z; Obal, I; Vecsei, L | 1 |
| Chitnis, S; Khemani, P; Patel, N; Samudra, N; Womack, KB | 1 |
| Blier, P; Drago, F; Nutt, D; Stahl, S; Wilson, S; Zohar, J | 1 |
| Hussar, DA | 1 |
| Bozymski, KM; Crouse, EL; Gatesman, TL; Lowe, DK; Pasternak, KM | 1 |
| Ensom, MHH; Johnson, EG; Johnson, HE; Wilby, KJ | 1 |
| Finn, LA; Hussar, DA | 1 |
| Andreason, P; Atrakchi, A; Avila, AM; Farchione, T; Mathis, MV; Muoio, BM; Temple, RJ | 1 |
| Cozac, VV | 1 |
| Alva, G; Arquette, S; Espay, AJ; Farnum, C; Hermanowicz, N; Kenney, J; Kremens, D; Lopes, M; Madrid, KC; Pagan, F; Patel, A; Tereso, G | 1 |
| Duffy, A; Farias, S; Malhado-Chang, N; O'Connor, K; Olichney, J; Shahlaie, K; Sperry, L; Wheelock, V; Yuan, M; Zhang, L | 1 |
| Atchison, C; Fredericks, D; Norton, JC; Pill, MW; Schoenhaus, R | 1 |
| Aarsland, D; Ballard, C; Ffytche, D; Velayudhan, L | 1 |
| Bae, IH; Burns, A; Choi, G; Choi, JK; Fagg, R; Gatfield, KM; Lee, CS; Naidoo, AA; Park, M; Park, YH; Powell, AJ; Vidgeon-Hart, M | 1 |
| Kianirad, Y; Simuni, T | 1 |
| Sahli, ZT; Tarazi, FI | 1 |
| Chi-Burris, K; Citrome, L; Demos, G; Norton, JC | 1 |
| Chen, X; Chu, Y; Sun, X; Wang, S; Wang, Y; Wu, W; Zhang, J | 1 |
| Hermanowicz, N | 2 |
| Ondo, WG; Panchal, SC | 1 |
| Schneider, LS | 2 |
| Ballard, C; Banister, C; Coate, B; Cummings, J; Demos, G; Khan, Z; Owen, R; Stankovic, S; Youakim, JM | 1 |
| Webster, P | 1 |
| Ahmad, A; Bulica, B; Kaminski, P; Krstevska, S; LeWitt, P; Mahajan, A; Patel, N; Taylor, D | 1 |
| Schubmehl, S; Sussman, J | 2 |
| Butala, AA; Pontone, GM | 1 |
| Gandhi, R; Lessig, SL; Litvan, I; Moreno, GM; Nahab, FB; Wright, B | 1 |
| Jalal, B | 1 |
| Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J | 1 |
| Andersson, C; Ballard, C; Coate, B; Espay, AJ; Factor, SA; Fredericks, D; Friedman, JH; Guskey, MT; Lang, AE; Larsen, NJ; Norton, JC; Vizcarra, JA; Weintraub, D | 1 |
| Ballard, C; Coate, B; Stankovic, S; Youakim, JM | 1 |
| Citrome, L | 1 |
| Adler, CH; Alva, G; Black, KJ; Cooney, JW; Isaacson, S; Kremens, D; Menza, MA; Meyer, JM; Morrissette, DA; Nasrallah, H; Pahwa, R; Patkar, AA; Simuni, T; Stacy, M; Stahl, SM | 1 |
| Canal, C; de la Cruz, J | 1 |
| Clemons, WM; Eslamimehr, S; Ishizaki, Y; Kurosu, M; Kurosu, SM; Lemieux, MR; Mitachi, K | 1 |
| Fedora, R; Morton, R; Nasrallah, HA | 1 |
| Burstein, ES | 1 |
| Claassen, DO; Darby, RR; Farooque, A; Sellers, J | 1 |
| Boren, CB; Boren, RA | 1 |
| Lippmann, S; Mohanty, D; Naik, S; Sarai, S | 1 |
| Bertini, S; Digiacomo, M; Gado, F; Macchia, M; Manera, C; Meini, S | 1 |
| Dirks, B; Fava, M; Freeman, MP; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH | 1 |
| Dahodwala, N; Horn, S; Richardson, H; Weintraub, D; Xie, SX | 1 |
| Andersen, ML; Dokkedal-Silva, V; Galduróz, JCF; Morelhão, PK; Tufik, S | 1 |
| Desai, R; Jain, S; Mansuri, Z; Patel, K; Zafar, MK | 1 |
| Hemine, K; Kernstein, A; Kozłowska-Tylingo, K; Skwierawska, A | 1 |
| Alamein, C; Canals, M; Christie, MJ; Connor, M; Fritzwanker, S; Gillis, A; Gondin, AB; Grimsey, NL; Halls, ML; Kassiou, M; Katte, TA; Kellam, B; Kliewer, A; Krasel, C; Lane, JR; Lim, HD; Manandhar, P; Reekie, T; Sanchez, J; Santiago, M; Schmiedel, F; Schulz, S | 1 |
| Dirks, B; Fava, M; Freeman, MP; Jha, MK; Liu, K; Papakostas, GI; Shelton, RC; Stankovic, S; Thase, ME; Trivedi, MH | 4 |
| Bronstein, JM; Kyle, K | 2 |
| Jukić, MM | 1 |
| Cannavò, D; Caraci, F; Caruso, G; Drago, F; Leggio, GM; Salomone, S; Santagati, M | 1 |
| Abler, V; Azulay, JP; Ballard, CG; Demos, G; Fernandez, HH; Ferreira, JJ; Ilic, TV; Isaacson, S; Kreitzman, DL; Liu, IY; Norton, JC; Stankovic, S | 1 |
| Coate, B; Isaacson, SH; Norton, J; Stankovic, S | 1 |
| Abler, V; Ballard, CG; Coate, B; Foff, E; Stankovic, S | 1 |
| Abler, V; Aldred, JL; Alva, G; Cantillon, M; Coate, B; DeKarske, D; Jacobi, L; Norton, JC; Nunez, R | 1 |
| Cummings, JL; Devanand, DP; Stahl, SM | 1 |
| Alexander, GC; Mehta, HB; Moore, TJ | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Cumming, P; Gründer, G | 1 |
| Jha, MK; Murrough, J; Ruberto, VL; Soogrim, V | 1 |
| Channe Gowda, D; Kumara, HK; Pavan Kumar, H; Suhas, R | 1 |
| Abler, V; Azulay, JP; Ballard, CG; Coate, B; Fernandez, HH; Ferreira, JJ; Ilic, TV; Isaacson, SH; Kreitzman, DL; Norton, JC; Stankovic, S | 1 |
| Aalapati, KK; Patnaik, RS; Singh, A | 1 |
| Atanasovski, D; Eriksson, E; Hagsäter, SM; Näslund, J; Pettersson, C; Pettersson, R | 1 |
| Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM | 1 |
| Friedman, JI | 1 |
| Fan, RC; Gao, XQ; Ji, LZ; Jia, YP; Li, HL; Li, P; Liu, XN; Liu, ZZ; Tang, B; Wang, YQ; Yang, MQ; Zhang, QK; Zhou, YQ | 1 |
| Ali, F | 1 |
| Alexander, GC; An, H; Hwang, YJ; Mehta, HB; Moore, TJ | 1 |
| Howard, R; Liu, KY | 1 |
| Abbasnejad, M; Esmaeili-Mahani, S; Kooshki, R; Pourrahimi, AM; Raoof, M | 1 |
| Li, X; Tian, X | 1 |
| Abbs, B; Arango, C; Bugarski-Kirola, D; Fava, M; Liu, IY; Nasrallah, H; Stankovic, S | 1 |
| Badria, FA; El-Domany, RA; El-Senduny, FF; Eldehna, WM; Elgazar, AA; Elimam, DM | 1 |
| Burstein, ES; Elzokaky, A; Meltzer, HY; Rajagopal, L; Ryan, C | 1 |
| Dong, Z; He, L; Jiang, Y; Liu, K; Lu, X; Wang, Z; Wei, Y; Wu, W; Wu, X; Yu, Y; Yuan, Q; Zhao, J; Zhao, L; Zhou, H | 1 |
| Doshi, D; Subbiah, P; Turner, ME | 1 |
| Alexander, GC; Hwang, YJ; Mehta, HB; Moore, TJ | 1 |
| Ballard, C; Cummings, JL; Devanand, DP; Sultzer, DL; Tariot, PN | 1 |
| Adegbenle, YH; Bokser, AD; Norton, JC; Stoisavljevic, V | 1 |
| Crump, CJ; El-Mallakh, RS; Elsayed, OH; Litteral, CA | 1 |
| Isaacson, SH; Pagan, F; Pahwa, R; Sabbagh, M; Small, GW; Torres-Yaghi, Y | 1 |
| Akhtar, S; Feng, Y; Graham, DJ; Kelman, JA; Leishear, K; Liao, J; Lyu, H; Ma, Y; MaCurdy, TE; Mosholder, AD; Nelson, LM; Podskalny, GD; Wei, Y; Wernecke, M | 1 |
| Colijn, MA | 1 |
36 review(s) available for urea and piperidines
| Article | Year |
|---|---|
ACP-103, a 5-HT2A receptor inverse agonist.
Topics: Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Humans; Piperidines; Receptor, Serotonin, 5-HT2A; Serotonin Receptor Agonists; Structure-Activity Relationship; Urea | 2006 |
Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders.
Topics: Clinical Trials as Topic; Humans; Molecular Structure; Parkinson Disease; Piperidines; Schizophrenia; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Urea | 2008 |
Parkinson's disease dementia.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Diagnosis, Differential; Humans; Parkinson Disease; Piperidines; Urea | 2010 |
Serotonin 2A receptor antagonists for treatment of schizophrenia.
Topics: Antipsychotic Agents; Brain; Fluorobenzenes; Humans; Phenols; Piperidines; Positron-Emission Tomography; Receptor, Serotonin, 5-HT2A; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Urea | 2011 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Animals; Antiparkinson Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Urea | 2013 |
Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.
Topics: Benzazepines; Diabetes Mellitus, Type 2; Heart Valve Diseases; Humans; Molecular Structure; Obesity; Parkinson Disease; Piperidines; Receptors, Serotonin; Schizophrenia; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Urea | 2013 |
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis.
Topics: Drug Discovery; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2014 |
Treating psychosis in movement disorder patients: a review.
Topics: Animals; Antipsychotic Agents; Clozapine; Humans; Movement Disorders; Piperidines; Psychotic Disorders; Treatment Outcome; Urea | 2014 |
Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
Topics: Alzheimer Disease; Apathy; Citalopram; Clinical Trials as Topic; Cognition Disorders; Humans; Mental Disorders; Piperidines; Research Design; Therapies, Investigational; Treatment Outcome; Urea | 2015 |
Pimavanserin.
Topics: Animals; Clinical Trials as Topic; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2015 |
Overview of CDK9 as a target in cancer research.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Flavonoids; Humans; Indolizines; Molecular Targeted Therapy; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridinium Compounds; Roscovitine; Thiazoles; Urea | 2016 |
Pimavanserin: First Global Approval.
Topics: Antipsychotic Agents; Delusions; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Hallucinations; Humans; Molecular Structure; Parkinson Disease; Piperidines; Randomized Controlled Trials as Topic; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Urea | 2016 |
Pimavanserin for the treatment of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Schizophrenia; Serotonin 5-HT2 Receptor Agonists; Urea | 2016 |
Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
Topics: Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Humans; Molecular Targeted Therapy; Neurotransmitter Agents; Parkinson Disease; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Urea | 2016 |
Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2017 |
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parkinson Disease; Piperazines; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; Urea | 2017 |
The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; United States; United States Food and Drug Administration; Urea | 2017 |
The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis.
Topics: Animals; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Urea | 2017 |
Parkinson's disease and Parkinson's disease psychosis: a perspective on the challenges, treatments, and economic burden.
Topics: Antipsychotic Agents; Cost of Illness; Health Care Costs; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2017 |
New Therapeutic Strategies for Lewy Body Dementias.
Topics: alpha-Synuclein; Cholinesterase Inhibitors; Disease Management; Genetic Therapy; Humans; Lewy Body Disease; Parkinson Disease; Piperidines; Stem Cell Transplantation; Urea | 2017 |
Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Delusions; Drug Inverse Agonism; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2017 |
Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
Topics: Animals; Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2018 |
Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Clinical Trials as Topic; Humans; Numbers Needed To Treat; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2018 |
Delusional misidentification in Parkinson's disease: report of two cases and a review.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Delusions; Female; Humans; Male; Parkinson Disease; Piperidines; Urea | 2018 |
Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis.
Topics: Antipsychotic Agents; Delusions; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2018 |
Pharmacological interventions for psychosis in Parkinson's disease patients.
Topics: Antipsychotic Agents; Clozapine; Dopamine; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Urea | 2018 |
The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.
Topics: Animals; Dopamine; Hallucinations; Hallucinogens; Humans; Lysergic Acid Diethylamide; Neuropharmacology; Piperidines; Psilocybin; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Sleep; Sleep Paralysis; Urea | 2018 |
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia; Humans; Mental Status and Dementia Tests; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Severity of Illness Index; Treatment Outcome; Urea | 2018 |
Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
Topics: Antiparkinson Agents; Antipsychotic Agents; Consensus; Drug Substitution; Humans; Off-Label Use; Parkinson Disease; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2018 |
Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery.
Topics: Allosteric Regulation; Drug Design; Humans; Indoles; Piperidines; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Urea | 2019 |
Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.
Topics: Antipsychotic Agents; Humans; Lewy Body Disease; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2020 |
New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
Topics: Alzheimer Disease; Antipsychotic Agents; Anxiety; Humans; Piperidines; Psychotic Disorders; Quinolones; Thiophenes; Urea | 2020 |
Dementia-related psychosis and the potential role for pimavanserin.
Topics: Dementia; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Humans; Piperidines; Receptors, Serotonin; Urea | 2021 |
Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis.
Topics: Alzheimer Disease; Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Urea | 2023 |
27 trial(s) available for urea and piperidines
| Article | Year |
|---|---|
A controlled study of clopamide, clorexolone, and hydrochlorothiazide in diabetics.
Topics: Adult; Aged; Amides; Blood Glucose; Blood Pressure; Body Weight; Clinical Trials as Topic; Clopamide; Diabetes Mellitus; Diuretics; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Piperidines; Placebos; Potassium; Sulfonamides; Urea | 1973 |
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alanine; Anti-Ulcer Agents; Breath Tests; False Negative Reactions; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Piperidines; Predictive Value of Tests; Quinolones; Urea | 2003 |
Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Half-Life; Humans; Male; Middle Aged; Piperidines; Serotonin 5-HT2 Receptor Agonists; Urea | 2007 |
The effects of food on the pharmacokinetics of a formulated ACP-103 tablet in healthy volunteers.
Topics: Adolescent; Adult; Antipsychotic Agents; Biological Availability; Cross-Over Studies; Fasting; Food-Drug Interactions; Half-Life; Humans; Male; Middle Aged; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Tablets; Therapeutic Equivalency; Urea | 2007 |
PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Binding, Competitive; Brain; Carbon Radioisotopes; Dose-Response Relationship, Drug; Drug Inverse Agonism; Humans; Male; Piperidines; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, Serotonin, 5-HT2A; Spiperone; Urea | 2008 |
Hypotensive anesthesia with propofol and remifentanil: protective effect of alpha-tocopherol on renal function.
Topics: Acetylglucosaminidase; Adult; alpha-Tocopherol; Anesthesia, Intravenous; Anesthetics, Intravenous; Antioxidants; Female; Humans; Hypotension; Hypotension, Controlled; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Piperidines; Propofol; Remifentanil; Sodium; Urea | 2008 |
Effect of landiolol on bispectral index and spectral entropy responses to tracheal intubation during propofol anaesthesia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anesthetics, Intravenous; Double-Blind Method; Electroencephalography; Entropy; Female; Humans; Intubation, Intratracheal; Male; Middle Aged; Monitoring, Intraoperative; Morpholines; Piperidines; Propofol; Remifentanil; Signal Processing, Computer-Assisted; Urea | 2008 |
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Topics: Aged; Analysis of Variance; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Motor Activity; Parkinson Disease; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Severity of Illness Index; Urea | 2010 |
Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers.
Topics: Adult; Aged; Double-Blind Method; Female; Human Experimentation; Humans; Male; Middle Aged; Patient Compliance; Piperidines; Placebo Effect; Polysomnography; Serotonin 5-HT2 Receptor Antagonists; Sleep; Urea | 2011 |
[Effect of landiolol on bispectral index scores in patients undergoing lower abdominal surgery].
Topics: Adrenergic beta-Antagonists; Adult; Anesthesia; Consciousness Monitors; Female; Humans; Hysterectomy; Methyl Ethers; Middle Aged; Morpholines; Piperidines; Remifentanil; Sevoflurane; Urea | 2012 |
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Time Factors; Urea; Young Adult | 2012 |
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Treatment Outcome; Urea | 2014 |
Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.
Topics: Accidental Falls; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Antipsychotic Agents; Drug Therapy, Combination; Edema; Female; Humans; Hypotension, Orthostatic; Infections; Male; Middle Aged; Parkinson Disease; Piperidines; Psychotic Disorders; Stroke; Thromboembolism; Urea | 2015 |
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Nursing Homes; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Treatment Outcome; Urea | 2018 |
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Mental Status Schedule; Middle Aged; Nootropic Agents; Parkinson Disease; Piperidines; Psychotic Disorders; Treatment Outcome; Urea | 2018 |
Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Nursing Homes; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome; Urea | 2019 |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
Topics: Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperidines; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Urea; Young Adult | 2019 |
Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Urea | 2020 |
Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
Topics: Aggression; Alzheimer Disease; Double-Blind Method; Humans; Piperidines; Psychomotor Agitation; Psychotic Disorders; Treatment Outcome; Urea | 2020 |
An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
Topics: Aged; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Piperidines; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin and Noradrenaline Reuptake Inhibitors; Urea | 2020 |
Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety; Depression; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Urea | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
Topics: Adult; Depression; Depressive Disorder, Major; Double-Blind Method; Humans; Piperidines; Suicidal Ideation; Urea | 2020 |
Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Piperidines; Serotonin 5-HT2 Receptor Antagonists; Sleep Wake Disorders; Treatment Outcome; Urea; Young Adult | 2020 |
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2021 |
Trial of Pimavanserin in Dementia-Related Psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Double-Blind Method; Female; Hallucinations; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Parkinson Disease; Piperidines; Proportional Hazards Models; Psychotic Disorders; Recurrence; Urea | 2021 |
Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
Topics: Adolescent; Adult; Double-Blind Method; Europe; Female; Humans; Male; Middle Aged; North America; Outcome Assessment, Health Care; Piperidines; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Urea; Young Adult | 2022 |
176 other study(ies) available for urea and piperidines
| Article | Year |
|---|---|
Quantitative structure-activity relationships. 1. The modified Free-Wilson approach.
Topics: Animals; Antifungal Agents; Cholinesterase Inhibitors; Epinephrine; Glycerol; Hypnotics and Sedatives; Kinetics; Models, Chemical; Phenethylamines; Phenyl Ethers; Piperidines; Propylene Glycols; Regression Analysis; Structure-Activity Relationship; Thyroxine; Urea | 1976 |
Post-operative convulsions. A review based on a case report.
Topics: Androstanes; Anesthesia, Inhalation; Aortic Aneurysm; Atropine; Autopsy; Blood Pressure; Calcium; Carbon Dioxide; Cerebrospinal Fluid Proteins; Gluconates; Glucose; Hematocrit; Humans; Male; Middle Aged; Neuromuscular Nondepolarizing Agents; Nitrous Oxide; Oxygen; Oxygen Consumption; Phenytoin; Piperidines; Postoperative Complications; Potassium; Respiration, Artificial; Seizures; Sodium; Thiopental; Urea | 1971 |
Mobility of the paramagnetic label bound by aspartate aminotransferase.
Topics: Aspartate Aminotransferases; Binding Sites; Cyclic N-Oxides; Drug Stability; Electron Spin Resonance Spectroscopy; Free Radicals; Hydrogen-Ion Concentration; Piperidines; Pyridoxal Phosphate; Urea | 1970 |
Urea denaturation of active-site spin-labeled -chymotrypsin.
Topics: Binding Sites; Chymotrypsin; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Fluorine; Hydrogen-Ion Concentration; Organophosphorus Compounds; Piperidines; Protein Denaturation; Pyrroles; Urea | 1972 |
Effect of denaturation on muscle proteins as studied by Epr.
Topics: Action Potentials; Animals; Anura; Electron Spin Resonance Spectroscopy; Guanidines; Hindlimb; Mathematics; Muscle Proteins; Muscles; Piperidines; Protein Conformation; Protein Denaturation; Rabbits; Rana esculenta; Spin Labels; Time Factors; Urea | 1973 |
[A spray reagent combination for differential determination of methyprylon from its main metabolite methylpersedon as well as a selection of hypnotics and eukraton on thin layer chromatograms].
Topics: Barbiturates; Bemegride; Chromatography, Thin Layer; Glutethimide; Hexobarbital; Hypnotics and Sedatives; Indicators and Reagents; Methaqualone; Phenobarbital; Piperidines; Urea | 1969 |
Electrostatic effects in the interaction of polyuridylic acid with N-(2,2,6,6-tetramethyl-1-oxylpiperidin-4-yl)-N'-(beta-(4-methylmorpholinio) ethyl)-carbodiimide.
Topics: Binding Sites; Carbodiimides; Carbon Radioisotopes; Cyclic N-Oxides; Kinetics; Mathematics; Morpholines; Nucleic Acid Conformation; Osmolar Concentration; Piperidines; Poly U; Sodium Chloride; Temperature; Time Factors; Uracil; Urea; Uridine | 1974 |
Synthesis and antiarrhythmic activity of 5,5-disubstituted-3-aminoalkylhydantions and some heterocyclic and noncyclic analogues.
Topics: Alkylation; Amides; Animals; Arrhythmias, Cardiac; Diethylamines; Dimethylamines; Disopyramide; Heterocyclic Compounds; Hydantoins; Isomerism; Mice; Piperidines; Quinidine; Structure-Activity Relationship; Urea; Ventricular Fibrillation | 1974 |
Nitrosation of tertiary amines and some biologic implications.
Topics: Amines; Carcinogens; Dealkylation; Dimethylamines; Dimethylformamide; Environmental Exposure; Ethanolamines; Food Additives; Humans; Hydrogen-Ion Concentration; Methylamines; Morpholines; Naphthalenes; Neoplasms; Nitrites; Nitrosamines; p-Dimethylaminoazobenzene; Piperazines; Piperidines; Propylamines; Pyrrolidines; Temperature; Time Factors; Urea | 1972 |
[Conversion of 2,4-dioxo- and 2-oxo-4-thioxo-5,6-benzodihydro-1,3-oxazines with amines].
Topics: Amines; Anilides; Benzamides; Chemical Phenomena; Chemistry; Imines; Methylation; Oxazines; Piperidines; Temperature; Urea | 1973 |
Thermographic, hormonal, and clinical studies in migraine.
Topics: Body Temperature; Cycloheptanes; Cyproheptadine; Ergolines; Female; Humans; Menstruation; Methysergide; Migraine Disorders; Phenothiazines; Piperidines; Progesterone; Reserpine; Serotonin Antagonists; Skin Temperature; Thermography; Thiophenes; Urea | 1970 |
[Therapy of anxiety, mental anguish and sleeplessness. 1. Chemical survey].
Topics: Azepines; Barbiturates; Phenothiazines; Piperidines; Propylene Glycols; Urea | 1969 |
Sulfamylurea hypoglycemic agents. I. Synthesis and screening.
Topics: Amides; Amines; Animals; Heterocyclic Compounds; Hypoglycemic Agents; Piperidines; Rats; Sulfonamides; Urea | 1965 |
Sulfamylurea hypoglycemic agents. 3. Tetrasubstituted sulfamylureas and N-sulfamylcarbamates.
Topics: Amides; Amines; Carbamates; Chemical Phenomena; Chemistry; Hypoglycemic Agents; Piperidines; Urea | 1965 |
Involvement of 5-HT2A receptors in the elevation of rat serum corticosterone concentrations by quipazine and MK-212.
Topics: Animals; Corticosterone; Fluorobenzenes; Indoles; Male; Piperidines; Pyrazines; Quipazine; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Urea | 1996 |
Effect of selective blockade of endothelin ETB receptors on the liver dysfunction and injury caused by endotoxaemia in the rat.
Topics: Alanine Transaminase; Analysis of Variance; Animals; Aspartate Aminotransferases; Azepines; Blood Pressure; Creatinine; Endotoxemia; Escherichia coli; Heart Rate; Hypotension; Lipopolysaccharides; Male; Nitric Oxide; Oligopeptides; Piperidines; Rats; Rats, Wistar; Shock, Septic; Urea | 1996 |
Serotonin inhibition of the NMDA receptor/nitric oxide/cyclic GMP pathway in rat cerebellum: involvement of 5-hydroxytryptamine2C receptors.
Topics: Adrenergic alpha-Antagonists; Animals; Cerebellum; Cyclic GMP; Excitatory Amino Acid Agonists; Fluorobenzenes; Indoles; Male; N-Methylaspartate; Nitric Oxide; Organ Culture Techniques; Phenols; Piperidines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2C; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Urea; Yohimbine | 1997 |
Salutary antiarrhythmic effect of combining a K channel blocker and a beta-blocker in a canine model of 7-day-old myocardial infarction.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Drug Therapy, Combination; Electrocardiography; Female; Heart; Heart Ventricles; Male; Morpholines; Myocardial Infarction; Piperidines; Potassium Channel Blockers; Pyridines; Urea | 2000 |
The effect of the acute administration of various selective 5-HT receptor antagonists on focal hippocampal seizures in freely-moving rats.
Topics: Animals; Dose-Response Relationship, Drug; Electroencephalography; Fluorobenzenes; Granisetron; Hippocampus; Indoles; Locomotion; Male; Piperazines; Piperidines; Pyridines; Rats; Rats, Wistar; Receptors, Serotonin; Seizures; Serotonin Antagonists; Severity of Illness Index; Urea | 2000 |
CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model.
Topics: Animals; Cell Line; Chemokine CCL3; Chemokine CCL4; Creatinine; Disease Models, Animal; Graft Rejection; Graft Survival; Humans; Jurkat Cells; Kidney Transplantation; Macrophage Inflammatory Proteins; Phenylurea Compounds; Piperidines; Rabbits; Receptors, CCR1; Receptors, Chemokine; Transplantation, Homologous; Urea | 2001 |
4-Aminopiperidine ureas as potent selective agonists of the human beta(3)-adrenergic receptor.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-Agonists; Animals; Humans; Mice; Mice, Transgenic; Piperidines; Urea | 2001 |
Improvement of physicochemical properties of N-4472 part I formulation design by using self-microemulsifying system.
Topics: Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Chromatography, High Pressure Liquid; Emulsions; Excipients; Hypolipidemic Agents; Particle Size; Piperidines; Solubility; Solvents; Spectrophotometry, Ultraviolet; Temperature; Urea | 2002 |
Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.
Topics: Animals; Anti-Allergic Agents; Calcium; Chemokine CCL11; Chemokines, CC; Chemotaxis, Leukocyte; CHO Cells; Cricetinae; Eosinophils; Humans; In Vitro Techniques; Piperidines; Receptors, CCR3; Receptors, Chemokine; Structure-Activity Relationship; Urea | 2002 |
Improvement of physicochemical properties of N-4472. Part II: characterization of N-4472 microemulsion and the enhanced oral absorption.
Topics: Administration, Oral; Animals; Ascorbic Acid; Castor Oil; Drug Stability; Emulsions; Excipients; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Male; Particle Size; Piperidines; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Sodium Dodecyl Sulfate; Solubility; Urea; Water | 2002 |
Rapid liquid-phase combinatorial synthesis of heterocyclic libraries.
Topics: Benzimidazoles; Combinatorial Chemistry Techniques; Guanidine; Guanidines; Heterocyclic Compounds; Magnetic Resonance Spectroscopy; Piperidines; Urea | 2002 |
Improvement of physicochemical properties of N-4472. Part III. VC/N-4472 complex formation and self-association in aqueous solution.
Topics: Acids; Carboxylic Acids; Chemical Phenomena; Chemistry, Physical; Piperidines; Solutions; Urea; Water | 2003 |
Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin.
Topics: Acetic Acid; Amino Acid Chloromethyl Ketones; Animals; Behavior, Animal; Capillary Permeability; Endothelins; Evans Blue; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Hyperalgesia; Indazoles; Injections, Intraperitoneal; Male; Mice; N-Methylaspartate; Nociceptors; Oligopeptides; Pain Measurement; Peptide Fragments; Peptides, Cyclic; Physical Stimulation; Piperidines; Reaction Time; Receptor, Endothelin A; Receptor, Endothelin B; Thrombin; Urea | 2003 |
[Hallucinations in chronic misuse of adaline; manifestations and clinical aspects of exogenic psychotic syndromes].
Topics: Bridged-Ring Compounds; Hallucinations; Humans; Mental Disorders; Piperidines; Psychotic Disorders; Syndrome; Urea | 1956 |
[Increasing incidence of adaline exanthems].
Topics: Bridged-Ring Compounds; Bromides; Exanthema; Humans; Hypnotics and Sedatives; Incidence; Piperidines; Skin Diseases; Urea | 1959 |
The diphasic effect of N-methyl-3-piperidyl-(N',N')-diphenylcarbamate HCI (MPDC) on the metabolism of hexobarbital.
Topics: Hexobarbital; Humans; Piperidines; Urea | 1961 |
[On the detection of carbromal (Adaline) and its metabolites].
Topics: Bridged-Ring Compounds; Hypnotics and Sedatives; Piperidines; Urea | 1963 |
[Chronic hallucinations with paranoid features due to misuse of carbromal (Diacid, Adaline)].
Topics: Bridged-Ring Compounds; Bromine; Hallucinations; Humans; Hypnotics and Sedatives; Paranoid Disorders; Piperidines; Substance-Related Disorders; Urea | 1962 |
RETENTION OF ALIPHATIC AMINES IN URAEMIA.
Topics: Amines; Ammonia; Blood; Body Fluids; Cerebrospinal Fluid; Chromatography; Dinitrophenols; Geriatrics; Humans; Piperidines; Pyrroles; Urea; Uremia; Urine; Urologic Diseases | 1963 |
[ADDITIONAL CLASSES OF COMPOUNDS INHIBITING TUMORS. I. CYTOSTATIC EFFECTS OF N- AND S-HYDROXYMETHYL COMPOUNDS].
Topics: Amides; Animals; Antineoplastic Agents; Benzimidazoles; Carbohydrate Metabolism; Carcinoma, Ehrlich Tumor; Cytostatic Agents; Formaldehyde; Hydantoins; Imidazoles; Isonicotinic Acids; Mice; Morpholines; Neoplasms, Experimental; Niacin; Niacinamide; Piperazines; Piperidines; Pyrroles; Research; Urea | 1963 |
Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.
Topics: Animals; Cattle; CHO Cells; Cricetinae; Piperidines; Protein Binding; Receptors, CCR3; Receptors, Chemokine; Urea | 2004 |
[Adaline toxicoderma with clinical aspect of Gougerot-Blum's pigmented purpuric lichenoid dermatitis].
Topics: Bridged-Ring Compounds; Dermatitis; Humans; Pharmaceutical Preparations; Piperidines; Purpura; Skin Diseases; Urea | 1950 |
Modulators of the human CCR5 receptor. Part 1: Discovery and initial SAR of 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.
Topics: Amides; Humans; Piperidines; Receptors, CCR5; Structure-Activity Relationship; Urea | 2005 |
N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.
Topics: Calcium Signaling; Chemokine CCL11; Chemokines, CC; Drug Interactions; Eosinophils; Humans; Inhibitory Concentration 50; Piperidines; Protein Binding; Receptors, CCR3; Receptors, Chemokine; Structure-Activity Relationship; Urea | 2005 |
Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.
Topics: Animals; Biological Availability; Caco-2 Cells; Calcium; Chemotaxis, Leukocyte; CHO Cells; Cricetinae; Cyclohexanes; Eosinophils; Female; Humans; Hypersensitivity; In Vitro Techniques; Inflammation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Permeability; Phenylurea Compounds; Piperidines; Receptors, CCR3; Receptors, Chemokine; Stereoisomerism; Structure-Activity Relationship; Urea | 2005 |
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Topics: Animals; Behavior, Animal; Biological Availability; Cloning, Molecular; Humans; Male; Mice; NIH 3T3 Cells; Piperidines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Urea | 2006 |
Comparative QSAR modeling of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas.
Topics: Amides; Piperidines; Quantitative Structure-Activity Relationship; Receptors, CCR5; Urea | 2006 |
Antimalarial activity of N-alkyl amine, carboxamide, sulfonamide, and urea derivatives of a dispiro-1,2,4-trioxolane piperidine.
Topics: Amines; Animals; Antimalarials; Humans; Malaria; Mice; Microsomes, Liver; Piperidines; Plasmodium berghei; Sulfonamides; Urea | 2006 |
Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists.
Topics: Animals; Chemical Phenomena; Chemistry, Physical; Chemotaxis; CHO Cells; Cricetinae; Cricetulus; Guanosine 5'-O-(3-Thiotriphosphate); In Vitro Techniques; Kinetics; Mice; Microsomes, Liver; Piperidines; Receptors, Chemokine; Receptors, CXCR3; Structure-Activity Relationship; Transfection; Urea | 2007 |
3D-QSAR studies of substituted 1-(3, 3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor antagonists.
Topics: CCR5 Receptor Antagonists; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Models, Chemical; Piperidines; Quantitative Structure-Activity Relationship; Reproducibility of Results; Static Electricity; Urea | 2007 |
Optimization of biaryl piperidine and 4-amino-2-biarylurea MCH1 receptor antagonists using QSAR modeling, classification techniques and virtual screening.
Topics: Drug Design; Models, Molecular; Piperidines; Quantitative Structure-Activity Relationship; Receptors, Somatostatin; Urea | 2007 |
Novel series of substituted biphenylmethyl urea derivatives as MCH-R1 antagonists for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Biphenyl Compounds; CHO Cells; Cricetinae; Cricetulus; Drug Design; Humans; Piperidines; Receptors, Somatostatin; Urea | 2007 |
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Haloperidol; Head Movements; Male; Mice; Mice, Inbred Strains; Motor Activity; Piperidines; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Urea | 2007 |
In vitro and in vivo antitumor effect of 5-FU combined with piplartine and piperine.
Topics: Alanine Transaminase; Alkaloids; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Benzodioxoles; Cell Proliferation; Dose-Response Relationship, Drug; Female; Fluorouracil; HL-60 Cells; Humans; Inhibitory Concentration 50; Kidney; Leukopenia; Liver; Mice; Piperidines; Piperidones; Polyunsaturated Alkamides; Sarcoma 180; Urea | 2008 |
Development of CXCR3 antagonists. Part 3: Tropenyl and homotropenyl-piperidine urea derivatives.
Topics: Animals; Cycloparaffins; Humans; Mice; Mice, Inbred BALB C; Models, Molecular; Piperidines; Receptors, CXCR3; Urea | 2008 |
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.
Topics: Administration, Oral; Animals; Chemotaxis, Leukocyte; Cytochrome P-450 Enzyme Inhibitors; Dogs; Eosinophils; Hydrogen Bonding; Mice; Molecular Conformation; Piperidines; Rats; Receptors, CCR3; Structure-Activity Relationship; Urea | 2008 |
From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.
Topics: Cyclization; Hydrogen Bonding; Molecular Conformation; Piperidines; Receptors, CCR3; Urea | 2008 |
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Piperidines; Positron-Emission Tomography; Psychomotor Agitation; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Urea | 2008 |
Prediction of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas based on the heuristic method, support vector machine and projection pursuit regression.
Topics: Amides; Artificial Intelligence; Humans; Piperidines; Quantitative Structure-Activity Relationship; Receptors, CCR5; Urea | 2009 |
A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.
Topics: Animals; Data Interpretation, Statistical; Dopamine Agents; Dyskinesia, Drug-Induced; Jaw; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Piperidines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Tremor; Urea | 2008 |
Diversity-oriented synthesis of a drug-like system displaying the distinctive N-->C=O interaction.
Topics: Aldehydes; Combinatorial Chemistry Techniques; Cyclization; HIV Protease; HIV-1; Hydrazines; Magnetic Resonance Spectroscopy; Molecular Conformation; Piperidines; Proline; Spectrophotometry, Ultraviolet; Stereoisomerism; Thermodynamics; Urea | 2008 |
Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.
Topics: Dose-Response Relationship, Drug; Enzyme Inhibitors; Molecular Structure; Piperidines; Stearoyl-CoA Desaturase; Structure-Activity Relationship; Substrate Specificity; Urea | 2008 |
Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation.
Topics: Aminopyridines; Animals; Antidepressive Agents, Second-Generation; Astrocytes; Butadienes; Calcium; Cells, Cultured; Chelating Agents; Dipeptides; Dose-Response Relationship, Drug; Egtazic Acid; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fluorobenzenes; Fluoxetine; Gene Expression; Indoles; Maleimides; Mice; Nitriles; Phosphorylation; Piperidines; Protein Kinase C; Proto-Oncogene Proteins c-fos; Quinazolines; Receptor, Serotonin, 5-HT2B; RNA, Messenger; Signal Transduction; Substrate Specificity; Transcriptional Activation; Tyrphostins; Up-Regulation; Urea | 2008 |
Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas--the effect of capping the distal basic piperidine nitrogen.
Topics: Allosteric Regulation; Allosteric Site; Amides; Benzimidazoles; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Design; Humans; Models, Chemical; Nitrogen; Piperidines; Receptor, Muscarinic M1; Structure-Activity Relationship; Sulfonamides; Urea | 2008 |
Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer.
Topics: Cell Shape; Cytochrome P-450 CYP2D6; Eosinophils; Humans; Molecular Structure; Piperidines; Protein Binding; Receptors, CCR3; Structure-Activity Relationship; Urea | 2009 |
Synthesis of spiro[chroman-2,4'-piperidin]-4-one derivatives as acetyl-CoA carboxylase inhibitors.
Topics: Acetyl-CoA Carboxylase; Adenosine Triphosphate; Animals; Carbohydrates; Chemistry, Pharmaceutical; Chromans; Drug Design; Inhibitory Concentration 50; Mice; Mice, Inbred C57BL; Models, Chemical; Piperidines; Spiro Compounds; Structure-Activity Relationship; Urea | 2009 |
Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH).
Topics: Amidohydrolases; Animals; Computer Simulation; Enzyme Inhibitors; Humans; Models, Chemical; Piperazines; Piperidines; Rats; Structure-Activity Relationship; Thiophenes; Urea | 2009 |
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Brain; Crystallography, X-Ray; Endocannabinoids; Enzyme Inhibitors; Humans; Male; Pain; Piperazine; Piperazines; Piperidines; Polyunsaturated Alkamides; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Structure-Activity Relationship; Urea | 2009 |
Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Eating; Humans; Mice; Piperidines; Rats; Receptors, Neuropeptide Y; Spiro Compounds; Urea; Weight Loss | 2009 |
Optimization of piperidin-4-yl-urea-containing melanin-concentrating hormone receptor 1 (MCH-R1) antagonists: Reducing hERG-associated liabilities.
Topics: Animal Feed; Animals; Cell Line; Chemistry, Pharmaceutical; Drug Design; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Feeding Behavior; Humans; Inhibitory Concentration 50; Models, Chemical; Obesity; Piperidines; Protein Binding; Rats; Receptors, Pituitary Hormone; Urea | 2009 |
Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
Topics: Amidohydrolases; Animals; Azetidines; Catalysis; Chemistry, Pharmaceutical; Drug Design; Enzyme Inhibitors; Humans; Mice; Mice, Knockout; Models, Chemical; Piperidines; Rats; Receptor, Cannabinoid, CB1; Stereoisomerism; Urea | 2009 |
Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.
Topics: Animals; Biological Availability; Cell Line; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Eicosanoids; Epoxide Hydrolases; Epoxy Compounds; Humans; In Vitro Techniques; Ion Channels; Kidney; Mesenteric Arteries; Models, Molecular; Molecular Conformation; Muscle Relaxation; Muscle, Smooth, Vascular; Piperidines; Rats; Rats, Inbred SHR; Solubility; Stereoisomerism; Structure-Activity Relationship; Urea | 2009 |
Discovery of 3,3-disubstituted piperidine-derived trisubstituted ureas as highly potent soluble epoxide hydrolase inhibitors.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Blood Pressure; Epoxide Hydrolases; Humans; Hypertension; Models, Molecular; Piperidines; Protein Binding; Rats; Rats, Inbred SHR; Structure-Activity Relationship; Urea | 2009 |
Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Flavonoids; Genes, cdc; Growth Inhibitors; Humans; Irinotecan; Mice; Mice, Nude; Models, Statistical; Neoplasm Transplantation; Piperidines; Predictive Value of Tests; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.
Topics: Animals; Antipsychotic Agents; Dopamine D2 Receptor Antagonists; Drug Interactions; Drug Inverse Agonism; Female; Fluorobenzenes; Phencyclidine; Piperidines; Random Allocation; Rats; Rats, Long-Evans; Recognition, Psychology; Serotonin 5-HT2 Receptor Antagonists; Urea | 2010 |
Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.
Topics: Administration, Oral; Animals; Binding Sites; Computer Simulation; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Microsomes, Liver; Piperidines; Rats; Urea | 2010 |
Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists.
Topics: Animals; Ether-A-Go-Go Potassium Channels; Histamine Antagonists; Humans; Piperidines; Rats; Receptors, Histamine H3; Structure-Activity Relationship; Urea | 2010 |
Pungency of TRPV1 agonists is directly correlated with kinetics of receptor activation and lipophilicity.
Topics: Action Potentials; Alkaloids; Animals; Benzodioxoles; Capsaicin; Diterpenes; Ganglia, Spinal; Kinetics; Lipid Metabolism; Male; Neurons, Afferent; Pain; Patch-Clamp Techniques; Piperidines; Polyunsaturated Alkamides; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sensory Receptor Cells; Solubility; TRPV Cation Channels; Urea | 2010 |
The endogenous actions of hypothalamic peptides on brown adipose tissue thermogenesis in the rat.
Topics: Adipose Tissue, Brown; Animals; Benzoxazoles; Blotting, Western; Body Weight; Eating; Energy Metabolism; Hypothalamic Hormones; Ion Channels; Male; Melanins; Melanocyte-Stimulating Hormones; Mitochondrial Proteins; Naphthyridines; Orexin Receptors; Piperidines; Pituitary Hormones; Pyrimidines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Melanocortin, Type 3; Receptor, Melanocortin, Type 4; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Thermogenesis; Uncoupling Protein 1; Urea | 2010 |
1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.
Topics: Adamantane; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Epoxide Hydrolases; Humans; Male; Mice; Morphine; Pain; Piperidines; Rats; Rats, Sprague-Dawley; Solubility; Structure-Activity Relationship; Urea | 2010 |
Skin application of urea-containing cream affected cutaneous arterial sympathetic nerve activity, blood flow, and water evaporation.
Topics: Administration, Topical; Anesthetics, Intravenous; Animals; Consciousness; Emollients; Histamine Antagonists; Male; Maleates; Piperidines; Rats; Rats, Hairless; Rats, Wistar; Receptors, Histamine H3; Regional Blood Flow; Skin; Sympathetic Nervous System; Urea; Urethane; Water | 2011 |
Chemical stimulation of the lateral hypothalamus induces conditioned place preference in rats: Involvement of OX1 and CB1 receptors in the ventral tegmental area.
Topics: Animals; Benzoxazoles; Carbachol; Choice Behavior; Conditioning, Operant; Dose-Response Relationship, Drug; Hypothalamic Area, Lateral; Male; Naphthyridines; Neural Pathways; Orexin Receptors; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor Cross-Talk; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Reward; Urea; Ventral Tegmental Area | 2011 |
Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.
Topics: Alkyl and Aryl Transferases; Benzoxazoles; Cell Line; Cell Membrane; Cloning, Molecular; Cyclohexanols; Extracellular Signal-Regulated MAP Kinases; Humans; Intracellular Signaling Peptides and Proteins; Ligands; Naphthyridines; Neuropeptides; Orexin Receptors; Orexins; Phenylurea Compounds; Phosphorylation; Piperidines; Plasmids; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Rimonabant; Thiazoles; Urea | 2011 |
Acid- and base-catalysis in the mononuclear rearrangement of some (Z)-arylhydrazones of 5-amino-3-benzoyl-1,2,4-oxadiazole in toluene: effect of substituents on the course of reaction.
Topics: Alkalies; Amines; Biological Products; Catalysis; Dioxanes; Hydrazones; Hydrophobic and Hydrophilic Interactions; Kinetics; Molecular Structure; Oxadiazoles; Piperidines; Structure-Activity Relationship; Temperature; Toluene; Trichloroacetic Acid; Urea; Water | 2011 |
Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain.
Topics: Amidohydrolases; Animals; Enzyme Inhibitors; Humans; Inflammation; Male; Mice; Mice, Inbred C57BL; Pain; Piperidines; Pyridazines; Rats; Rats, Sprague-Dawley; Urea | 2011 |
Covalent inhibitors of fatty acid amide hydrolase: a rationale for the activity of piperidine and piperazine aryl ureas.
Topics: Amidohydrolases; Catalytic Domain; Crystallography, X-Ray; Molecular Dynamics Simulation; Piperazines; Piperidines; Quantum Theory; Structure-Activity Relationship; Urea; Water | 2011 |
Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Cytosol; Eicosanoids; Enzyme Inhibitors; Epoxide Hydrolases; Female; Inflammation; Liver; Macaca fascicularis; Phenylurea Compounds; Piperidines; Urea | 2012 |
Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease.
Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; Dyskinesias; Fenfluramine; Fluorobenzenes; Hyperkinesis; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Psychotic Disorders; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Sensory Gating; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Serotonin Receptor Agonists; Substantia Nigra; Tyrosine 3-Monooxygenase; Urea | 2011 |
Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition.
Topics: Analysis of Variance; Animals; Animals, Newborn; Arachidonic Acids; Benzoxazines; Benzoxazoles; Biphenyl Compounds; Calcium Channel Blockers; Cannabinoid Receptor Modulators; Disease Models, Animal; Electric Stimulation; Endocannabinoids; Enzyme Inhibitors; Estrenes; gamma-Aminobutyric Acid; Glycerides; In Vitro Techniques; Inhibitory Postsynaptic Potentials; Intracellular Signaling Peptides and Proteins; Lactones; Male; Morpholines; Naphthalenes; Naphthyridines; Neural Inhibition; Neural Pathways; Neuropeptides; Orexin Receptors; Orexins; Orlistat; Pain; Pain Measurement; Patch-Clamp Techniques; Periaqueductal Gray; Piperidines; Pyrazoles; Pyrrolidinones; Rats; Rats, Wistar; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Urea | 2011 |
Design, synthesis and antiepileptic properties of novel 1-(substituted benzylidene)-3-(1-(morpholino/piperidino methyl)-2,3-dioxoindolin-5-yl)urea derivatives.
Topics: Animals; Anticonvulsants; Electroshock; Epilepsy; Humans; Isatin; Male; Mice; Morpholinos; Piperidines; Rats; Rats, Wistar; Structure-Activity Relationship; Urea | 2011 |
Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity.
Topics: Animals; Blood-Brain Barrier; Calcium; Cell Line; Cell Membrane Permeability; Dogs; Drug Design; Humans; Ligands; Male; Piperidines; Pyrazoles; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Stereoisomerism; Structure-Activity Relationship; Urea | 2012 |
Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Diabetes Mellitus, Type 2; Enzyme Activation; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Mice; Mice, Obese; Molecular Structure; Piperidines; Structure-Activity Relationship; Urea | 2012 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Haloperidol; Isoindoles; Lurasidone Hydrochloride; Phencyclidine; Piperazines; Piperidines; Pyridines; Pyrimidines; Rats; Rats, Long-Evans; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin 5-HT2 Receptor Agonists; Thiazoles; Urea | 2012 |
Pimavanserin, a 5-HT2A receptor inverse agonist, reverses psychosis-like behaviors in a rodent model of Alzheimer's disease.
Topics: Alzheimer Disease; Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Disease Models, Animal; Drug Inverse Agonism; Male; Mice; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2012 |
Tonic and transient endocannabinoid regulation of AMPAergic miniature postsynaptic currents and homeostatic plasticity in embryonic motor networks.
Topics: Age Factors; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analgesics; Animals; Arachidonic Acids; Benzoxazines; Chick Embryo; Electric Stimulation; Endocannabinoids; Excitatory Amino Acid Agonists; Female; gamma-Aminobutyric Acid; Heterocyclic Compounds, 1-Ring; Homeostasis; Male; Morpholines; Motor Neurons; Naphthalenes; Nerve Net; Neuronal Plasticity; Patch-Clamp Techniques; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Signal Transduction; Spinal Cord; Synaptic Potentials; Urea | 2012 |
Is there room for new non-dopaminergic treatments in Parkinson's disease?
Topics: Antiparkinson Agents; Droxidopa; Humans; Parkinson Disease; Piperidines; Urea | 2013 |
Synthesis and structure-activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors.
Topics: Anti-Inflammatory Agents; Catalytic Domain; Epoxide Hydrolases; Humans; Inhibitory Concentration 50; Microsomes, Liver; Models, Molecular; Molecular Structure; Piperidines; Protease Inhibitors; Solubility; Structure-Activity Relationship; Urea; Vasodilator Agents | 2013 |
Is there room for non-dopaminergic treatment in Parkinson disease?
Topics: Antiparkinson Agents; Droxidopa; Humans; Parkinson Disease; Piperidines; Treatment Outcome; Urea | 2013 |
A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior.
Topics: Animals; Benzoxazoles; Conditioning, Operant; Cues; Drug-Seeking Behavior; Extinction, Psychological; Hypothalamus; Isoquinolines; Male; Mice; Microinjections; Naphthyridines; Nerve Tissue Proteins; Neurons; Nicotine; Nicotinic Agonists; Nucleus Accumbens; Orexin Receptor Antagonists; Orexin Receptors; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Prefrontal Cortex; Protein Kinase Inhibitors; Pyridines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Self Administration; Signal Transduction; Urea | 2013 |
Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase.
Topics: Animals; Benzodioxoles; Enzyme Inhibitors; HEK293 Cells; Humans; Mice; Monoacylglycerol Lipases; Piperazine; Piperazines; Piperidines; Rats; Substrate Specificity; Triazoles; Urea | 2013 |
Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
Topics: Amphetamine; Animals; Antiparkinson Agents; Antipsychotic Agents; Apomorphine; Clozapine; Dopamine; Dose-Response Relationship, Drug; Male; Parkinsonian Disorders; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Rats; Rats, Sprague-Dawley; Urea | 2013 |
Ligand binding analysis and screening by chemical denaturation shift.
Topics: Acetazolamide; Calorimetry; Carbonic Anhydrase I; HIV Protease; Humans; Hydrogen-Ion Concentration; Kinetics; Ligands; Mesylates; Oxalates; Piperidines; Protein Binding; Protein Conformation; Protein Denaturation; Spectrometry, Fluorescence; Temperature; Thermodynamics; Urea | 2013 |
Development and optimization of piperidyl-1,2,3-triazole ureas as selective chemical probes of endocannabinoid biosynthesis.
Topics: Dose-Response Relationship, Drug; Drug Discovery; Endocannabinoids; Enzyme Inhibitors; Humans; Lipoprotein Lipase; Molecular Structure; Piperidines; Structure-Activity Relationship; Triazoles; Urea | 2013 |
Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β-hydrolase domain containing 6 (ABHD6).
Topics: Animals; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Humans; Mice; Models, Animal; Molecular Structure; Monoacylglycerol Lipases; Piperidines; Structure-Activity Relationship; Triazoles; Urea | 2013 |
4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.
Topics: Administration, Oral; Animals; Body Weight; Diet; Enzyme Activation; Enzyme Inhibitors; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Protein Binding; Rats; Stearoyl-CoA Desaturase; Structure-Activity Relationship; Urea | 2013 |
Pimavanserin as treatment for Parkinson's disease psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2014 |
Parkinson disease: Pimavanserin could be useful for treating psychosis in Parkinson disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2013 |
Potent P2Y1 urea antagonists bearing various cyclic amine scaffolds.
Topics: Adenosine Diphosphate; Amines; Animals; Blood Platelets; Half-Life; Humans; Microsomes, Liver; Piperidines; Platelet Aggregation Inhibitors; Protein Binding; Purinergic P2Y Receptor Agonists; Rats; Receptors, Purinergic P2Y1; Structure-Activity Relationship; Urea | 2013 |
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Biological Availability; Clinical Trials, Phase II as Topic; Drug Discovery; Hep G2 Cells; Humans; Male; Microsomes, Liver; Models, Molecular; Piperidines; Pregnane X Receptor; Protein Conformation; Receptors, CCR1; Receptors, Steroid; Species Specificity; Urea; Valine | 2014 |
Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Haloperidol; Isoindoles; Memory Disorders; Phencyclidine; Piperazines; Piperidines; Pyrimidines; Random Allocation; Rats, Long-Evans; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Agonists; Urea | 2015 |
(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand.
Topics: Animals; Carbon Radioisotopes; Ligands; Methylation; Piperidines; Positron-Emission Tomography; Radiopharmaceuticals; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Swine; Urea | 2015 |
2,2- and 2,6-Diarylpiperidines by aryl migration within lithiated urea derivatives of tetrahydropyridines.
Topics: Cyclization; Lithium; Molecular Structure; Piperidines; Pyridines; Pyrroles; Urea | 2015 |
Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells.
Topics: Acetamides; Adalimumab; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dasatinib; Dose-Response Relationship, Drug; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Macrophages; Monocytes; Naphthalenes; Oxazines; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; RNA, Small Interfering; Signal Transduction; Synovial Membrane; Tumor Necrosis Factor-alpha; Urea | 2015 |
TRPV1 modulators: Synthesis and in vitro evaluation of 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives.
Topics: Amides; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Molecular Structure; Piperidines; Structure-Activity Relationship; TRPV Cation Channels; Urea | 2015 |
Microinjection of orexin-A into the rat locus coeruleus nucleus induces analgesia via cannabinoid type-1 receptors.
Topics: Analgesics; Analysis of Variance; Animals; Benzoxazoles; Carrier Proteins; Dose-Response Relationship, Drug; Formaldehyde; Locus Coeruleus; Male; Microinjections; Naphthyridines; Orexins; Pain; Pain Measurement; Piperidines; Pyrazoles; Rats; Rats, Wistar; Urea | 2015 |
Individual differences in orexin-I receptor modulation of motivation for the opioid remifentanil.
Topics: Analgesics, Opioid; Animals; Bacterial Outer Membrane Proteins; Behavior, Animal; Benzoxazoles; Conditioning, Operant; Economics, Behavioral; Escherichia coli Proteins; Individuality; Lipoproteins; Male; Motivation; Naphthyridines; Orexin Receptor Antagonists; Orexin Receptors; Piperidines; Rats; Rats, Sprague-Dawley; Remifentanil; Self Administration; Urea | 2017 |
Market watch: Upcoming market catalysts in Q2 2016.
Topics: Adrenergic Uptake Inhibitors; Antiparkinson Agents; Drug Approval; Drug Discovery; Humans; Piperidines; Tetrabenazine; United States; United States Food and Drug Administration; Urea | 2016 |
Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates.
Topics: Analgesics; Animals; Carbamates; Female; Guinea Pigs; Male; Mice; Piperidines; Rats; Rats, Wistar; Spectrum Analysis; Urea | 2016 |
Effects of 7-day repeated treatment with the 5-HT2A inverse agonist/antagonist pimavanserin on methamphetamine vs. food choice in male rhesus monkeys.
Topics: Animals; Choice Behavior; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Inverse Agonism; Feeding Behavior; Food; Macaca mulatta; Male; Methamphetamine; Piperidines; Reinforcement, Psychology; Self Administration; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Treatment Outcome; Urea | 2016 |
Pimavanserin: An Inverse Agonist Antipsychotic Drug.
Topics: Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Agonists; Urea | 2016 |
Pimavanserin (Nuplazid) for Parkinson's disease psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Drug Administration Schedule; Drug Costs; Drug Interactions; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Treatment Outcome; Urea | 2016 |
Pimavanserin approved for Parkinson's-related hallucinations, delusions.
Topics: Antiparkinson Agents; Delusions; Drug Approval; Drug Labeling; Hallucinations; Humans; Parkinson Disease; Piperidines; Urea | 2016 |
Functional interaction between orexin-1 and CB1 receptors in the periaqueductal gray matter during antinociception induced by chemical stimulation of the lateral hypothalamus in rats.
Topics: Animals; Benzoxazoles; Carbachol; Disease Models, Animal; Hypothalamic Area, Lateral; Male; Microinjections; Naphthyridines; Orexin Receptors; Orexins; Pain; Pain Measurement; Periaqueductal Gray; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Stimulation, Chemical; Urea | 2016 |
Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors.
Topics: Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Urea | 2016 |
Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Dopamine; Humans; Levodopa; Lewy Bodies; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Serotonin; Urea | 2016 |
Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
Topics: Animals; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Urea | 2017 |
Inverse agonists - What do they mean for psychiatry?
Topics: Animals; Humans; Mental Disorders; Piperidines; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Urea | 2017 |
New Drugs 2017, part 1.
Topics: Antibodies, Monoclonal, Humanized; Drug Approval; Drug Therapy; Humans; Insulin, Long-Acting; Piperazines; Piperidines; Polymers; Pyrrolidinones; United States; United States Food and Drug Administration; Urea | 2017 |
2017 New Drug Update.
Topics: Anti-Inflammatory Agents; Antipsychotic Agents; Drugs, Investigational; Dry Eye Syndromes; Gout Suppressants; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Peptides; Phenylalanine; Piperidines; Sulfones; Thioglycolates; Triazoles; Urea | 2017 |
[Modern approaches to treatment of psychosis in Parkinson's disease].
Topics: Antiparkinson Agents; Antipsychotic Agents; Clozapine; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Quetiapine Fumarate; Urea | 2016 |
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Olanzapine; Outcome and Process Assessment, Health Care; Parkinson Disease; Piperidines; Psychological Techniques; Psychotic Disorders; Quality of Life; Retrospective Studies; Urea | 2017 |
Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment.
Topics: Acrylamides; Animals; Anthracenes; Bridged Bicyclo Compounds, Heterocyclic; Capsaicin; Cell Line; Cell Proliferation; Cell Survival; Cocarcinogenesis; Female; Humans; Keratinocytes; Mice; Mice, Hairless; Piperidines; Primary Cell Culture; Pyridines; Pyrrolidines; Risk; Skin Neoplasms; TRPV Cation Channels; Urea | 2018 |
Investigation of metabolic profile of pimavanserin in rats by ultrahigh-performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry.
Topics: Administration, Oral; Animals; Bile; Chromatography, High Pressure Liquid; Feces; Fourier Analysis; Male; Mass Spectrometry; Piperidines; Rats, Sprague-Dawley; Tissue Distribution; Urea | 2018 |
Pimavanserin for patients with Alzheimer's disease psychosis.
Topics: Alzheimer Disease; Double-Blind Method; Humans; Piperidines; Psychotic Disorders; Urea | 2018 |
Pimavanserin evaluated by the FDA.
Topics: Antipsychotic Agents; Delusions; Drug Evaluation; Hallucinations; Humans; Parkinson Disease; Piperidines; United States; United States Food and Drug Administration; Urea | 2018 |
Difficult choices in treating Parkinson's disease psychosis.
Topics: Antipsychotic Agents; Drug Approval; Humans; Off-Label Use; Parkinson Disease; Piperidines; Psychotic Disorders; United States; United States Food and Drug Administration; Urea | 2018 |
Pimavanserin use in a movement disorders clinic: a single-center experience.
Topics: Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Male; Middle Aged; Movement Disorders; Piperidines; Retrospective Studies; Serotonin 5-HT2 Receptor Agonists; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Urea | 2018 |
Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Approval; Humans; Outcome Assessment, Health Care; Parkinson Disease; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Urea | 2018 |
Absence of Evidence Versus Evidence of Absence-SAPS-PD.
Topics: Humans; Piperidines; Urea | 2018 |
FDA Approval of Pimavanserin: Response to Absence of Evidence Versus Evidence of Absence-Pimavanserin and the SAPS-PD.
Topics: Humans; Piperidines; Urea | 2018 |
Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Humans; Male; Middle Aged; Parkinson Disease; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Survival Analysis; Treatment Outcome; Urea | 2018 |
Psychiatric commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
Topics: Antipsychotic Agents; Consensus; Humans; Neurodegenerative Diseases; Off-Label Use; Parkinson Disease; Piperidines; Psychotic Disorders; Quality of Life; Urea | 2018 |
Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
Topics: Antipsychotic Agents; Consensus; Humans; Off-Label Use; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2018 |
Can pimavanserin help patients with Parkinson disease psychosis?
Topics: Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Serotonin 5-HT2 Receptor Antagonists; Urea | 2019 |
Semisynthesis of an Anticancer DPAGT1 Inhibitor from a Muraymycin Biosynthetic Intermediate.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Molecular Conformation; N-Acetylglucosaminyltransferases; Nucleosides; Nucleotides; Peptides; Phenylurea Compounds; Piperidines; Structure-Activity Relationship; Urea; Uridine | 2019 |
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist.
Topics: Adult; Aged; Antipsychotic Agents; Clozapine; Delusions; Drug Resistance; Female; Hallucinations; Humans; Male; Middle Aged; Piperidines; Psychotic Disorders; Retrospective Studies; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; Urea; Young Adult | 2019 |
Should inverse agonists be defined by pharmacological mechanism or clinical effect?
Topics: Antiparkinson Agents; Antipsychotic Agents; Humans; Piperidines; Urea | 2019 |
Pimavanserin for Psychosis in Parkinson's Disease-Related Disorders: A Retrospective Chart Review.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Female; Humans; Male; Parkinson Disease; Piperidines; Psychotic Disorders; Retrospective Studies; Urea | 2019 |
Charles Bonnet Syndrome Treated With Pimavanserin.
Topics: Aged, 80 and over; Charles Bonnet Syndrome; Humans; Male; Piperidines; Serotonin 5-HT2 Receptor Antagonists; Urea | 2019 |
Pimavanserin for Parkinson Disease Psychosis.
Topics: Antiparkinson Agents; Antipsychotic Agents; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2019 |
Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Female; Humans; Lewy Body Disease; Male; Middle Aged; Parkinson Disease; Piperidines; Psychotic Disorders; Quetiapine Fumarate; Retrospective Studies; Urea | 2019 |
The use of Pimavanserin in the treatment of Parkinson's disease: a consideration of its effects on sleep.
Topics: Cross-Sectional Studies; Genotype; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Sleep; Urea | 2020 |
Pimavanserin: A 2019 Clarification on the FDA Update.
Topics: Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2019 |
Cyclodextrin polymers as efficient adsorbents for removing toxic non-biodegradable pimavanserin from pharmaceutical wastewaters.
Topics: Adsorption; beta-Cyclodextrins; Cellulose; Cyclodextrins; Industrial Waste; Pharmaceutical Preparations; Piperidines; Polymers; Urea; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical | 2020 |
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists.
Topics: Benzimidazoles; beta-Arrestins; HEK293 Cells; Humans; Piperidines; Receptors, Opioid, mu; Spiro Compounds; Thiophenes; Urea | 2020 |
Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Longitudinal Studies; Male; Middle Aged; Norepinephrine; Piperidines; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Dysfunction, Physiological; Treatment Outcome; Urea | 2020 |
Can G
Topics: Brain; GTP-Binding Protein alpha Subunits, Gq-G11; Humans; Piperidines; Psychotic Disorders; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists; Urea | 2020 |
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Female; Hallucinations; Humans; Male; Middle Aged; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2020 |
Association of Pharmaceutical Industry Payments to Physicians With Prescription and Medicare Expenditures for Pimavanserin.
Topics: Aged; Cross-Sectional Studies; Drug Industry; Health Expenditures; Humans; Medicare Part D; Physicians; Piperidines; Practice Patterns, Physicians'; Prescription Drugs; Prescriptions; Retrospective Studies; United States; Urea | 2021 |
Treatment of Psychosis in Parkinson's disease and sudden death.
Topics: Antipsychotic Agents; Death, Sudden; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2020 |
Serotonin and amyloid deposition: A link between depression and Alzheimer's disease?: An Editorial Highlight on "Pimavanserin, a 5HT
Topics: Alzheimer Disease; Animals; Brain; Depression; Disease Models, Animal; Mice; Mice, Transgenic; Pharmaceutical Preparations; Piperidines; Receptor, Serotonin, 5-HT2A; Serotonin; Serotonin 5-HT2 Receptor Agonists; Urea | 2021 |
Multitarget-directed therapeutics: (Urea/thiourea)
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Antioxidants; Heterocyclic Compounds; Humans; Isoxazoles; Lysine; Molecular Docking Simulation; Piperazines; Piperidines; Structure-Activity Relationship; Thiourea; Urea | 2021 |
A Fully Validated UHPLC-MS/MS Method for the Estimation of Pimavanserin in Human (K2EDTA) Plasma and its Application to a Clinical Pharmacokinetic Study.
Topics: Chromatography, High Pressure Liquid; Humans; Piperidines; Reproducibility of Results; Tandem Mass Spectrometry; Urea | 2022 |
A Complex Impact of Systemically Administered 5-HT2A Receptor Ligands on Conditioned Fear.
Topics: Animals; Behavior, Animal; Bridged Bicyclo Compounds; Conditioning, Classical; Fear; Fluorobenzenes; Ligands; Male; Methylamines; Piperidines; Psilocybin; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Urea | 2021 |
Pimavanserin in Dementia-Related Psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
Identification of pimavanserin tartrate as a potent Ca
Topics: Animals; Brain Neoplasms; Calcineurin; Calcineurin Inhibitors; Calcium Signaling; Calcium-Binding Proteins; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Female; Glioblastoma; HeLa Cells; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; NFATC Transcription Factors; Piperidines; Urea; Xenograft Model Antitumor Assays | 2021 |
Pimavanserin: A Friend or Foe in Parkinson Disease Psychosis.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2021 |
Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Medicare; Parkinson Disease; Piperidines; Psychotic Disorders; Retrospective Studies; United States; Urea | 2021 |
Pimavanserin and dementia-related psychosis: can HARMONY prevail?
Topics: Clinical Trials as Topic; Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
The involvement of orexin 1 and cannabinoid 1 receptors within the ventrolateral periaqueductal gray matter in the modulation of migraine-induced anxiety and social behavior deficits of rats.
Topics: Animals; Anxiety; Behavior, Animal; Benzoxazoles; Male; Migraine Disorders; Naphthyridines; Orexin Receptors; Periaqueductal Gray; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Neuropeptide; Social Behavior; Urea | 2021 |
The protective effects of Pimavanserin against cerebral ischemia-induced brain injury.
Topics: Animals; Blood-Brain Barrier; Cell Line; Endothelial Cells; Infarction, Middle Cerebral Artery; Mice; Piperidines; Protective Agents; Tight Junctions; Urea | 2021 |
Natural inspired piperine-based ureas and amides as novel antitumor agents towards breast cancer.
Topics: Alkaloids; Amides; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Piperidines; Polyunsaturated Alkamides; Protein Kinase Inhibitors; Structure-Activity Relationship; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Pimavanserin augments the efficacy of atypical antipsychotic drugs in a mouse model of treatment-refractory negative symptoms of schizophrenia.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Male; Mice; Mice, Inbred C57BL; Piperidines; Schizophrenia, Treatment-Resistant; Urea | 2022 |
Nuplazid suppresses esophageal squamous cell carcinoma growth in vitro and in vivo by targeting PAK4.
Topics: Cell Line, Tumor; Cell Proliferation; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans; p21-Activated Kinases; Piperidines; Urea | 2022 |
Reader Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Urea | 2022 |
Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease.
Topics: Aged; Hospitalization; Humans; Parkinson Disease; Piperidines; Urea | 2022 |
Pimavanserin and dementia-related psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
In Vitro Stability and Recovery Studies of Pimavanserin in Water and in Different Vehicles Orally Administered.
Topics: Adult; Aged; Hallucinations; Humans; Piperidines; Urea; Water | 2022 |
Pimavanserin for bipolar disorder.
Topics: Bipolar Disorder; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
Topics: Aged; Antipsychotic Agents; Cohort Studies; Female; Humans; Male; Medicare; Parkinson Disease; Piperidines; Psychotic Disorders; Retrospective Studies; United States; Urea | 2022 |
The Therapeutic Potential of Pimavanserin in the Treatment of Hallucinogen Induced Psychosis and Persistent Perceptual Symptoms.
Topics: Hallucinogens; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia.
Topics: Antipsychotic Agents; Dementia; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |